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Abstract
Background A novel ibuprofen (IBU) formulation,
Advil Film-Coated Tablets (IBUNa), was developed.
Objective Pharmacokinetic comparison of IBUNa versus
other IBU formulations.
Study Design Two randomized, single-dose, open-label,
five-way crossover pharmacokinetic studies.
Setting Inpatient research clinic.
Subjects Seventy-one healthy adult volunteers.
Intervention Study 1: In three periods, fasted subjects
received 400-mg IBU dose equivalents as IBUNa
2 9 256 mg, Advil Liqui-Gels (IBULG) 2 9 200 mg,
and Motrin IB (IBUMot) 2 9 200 mg tablets. In two
periods following a high-fat breakfast, subjects received
400-mg IBU dose equivalents as IBUNa 2 9 256 mg and
IBULG 2 9 200 mg. Study 2: In five study periods, fasted
subjects received 400-mg IBU dose equivalents as IBUNa
2 9 256 mg, Advil FastGel (IBUFG) 2 9 200 mg,
Nurofen (IBUNur) 2 9 200 mg, Advil
 (IBUAdv)
2 9 200 mg, and Nurofen Express containing IBU lysi-
nate (IBULys) 2 9 342 mg.
Main Outcome Measure Log-transformed area under the
plasma concentration versus time curve to last observable
concentration (AUCL) and maximum plasma concentration
(Cmax) were the primary pharmacokinetic parameters; time
to maximum measured plasma concentration (Tmax) was
analyzed post hoc.
Results IBUNa was bioequivalent to IBULG (fasted and
fed) and IBUFG and IBULys (fasted) for rate (Cmax) and
extent (AUCL) of IBU absorption. After fasting, AUCL was
bioequivalent for IBUNa and IBUMot, IBUAdv, and IBUNur,
but Cmax occurred significantly earlier with IBUNa. After
fasting, median IBUNa Tmax was comparable to that for
IBULG, IBUFG, and IBULys, but was much shorter than that
for IBUMot, IBUNur, and IBUAdv. Food slowed absorption
of IBUNa and IBULG similarly. All treatments were toler-
ated similarly.
Conclusion IBUNa is absorbed faster but to a similar
extent as standard IBU formulations.
Key Points
A novel formulation of ibuprofen sodium (IBUNa) is
absorbed faster than (but to a similar extent to)
standard ibuprofen (IBU) in healthy subjects; a
clinical study found it to provide faster pain relief
than standard IBU formulations in subjects with
dental pain.
IBUNa has a pharmacokinetic profile similar to that
of other faster-absorbed formulations of IBU.
All IBU formulations were well tolerated, most
adverse events were mild in nature, and no
significant safety findings were noted.
Trial Registration As these are pharmacokinetic studies, trial
registration was not done.
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1 Introduction
When treating acute pain, rapid onset of relief is desirable.
With ibuprofen (IBU), one of the most widely used non-
prescription analgesics available, pain relief is directly
related to IBU plasma levels [1]. Although IBU is almost
completely absorbed, allowing for nearly 100 % bioavail-
ability, the rate of absorption depends on dissolution of the
given formulation [2]. IBU, which is a carboxylic acid,
shows low solubility in aqueous acidic media such as that
which is found in the stomach [3]. As a result, meaningful
pain relief typically takes approximately 45 min after
ingestion of an over-the-counter (OTC) dose (400 mg) of
standard IBU [4, 5]. Patients experiencing acute painful
conditions such as headache, musculoskeletal pain, men-
strual cramps, or dental pain would benefit from a faster
onset of pain relief.
In an effort to provide more rapid pain relief, newer IBU
formulations have been designed to dissolve more readily
in the acidic environment of the stomach. Such formula-
tions include IBU salt conjugates [e.g., IBU lysinate
(IBULys), arginine (IBUArg), or sodium (IBUNa)] and gel-
atin capsules containing solubilized IBU that achieve
maximum plasma concentrations (Cmax) that are higher and
are reached earlier (time to maximum measured plasma
concentration; Tmax) than those found with standard IBU
tablets [2, 4, 6]. Clinically, IBUArg has been found to
provide a faster onset of pain relief versus standard IBU [4,
5, 7], while both IBULys [8] and solubilized IBU [9–11]
have demonstrated more rapid pain relief compared with
acetaminophen. Recently, a novel tablet formulation of
IBU sodium dihydrate has been developed that has a thin-
film coating and is manufactured using a patent-pending
process. This report details two studies evaluating the
pharmacokinetic profile of this new formulation in com-
parison with both standard IBU tablets and rapidly absor-
bed IBU formulations.
2 Methods
2.1 Study Design and Procedures
Two single-dose, randomized, open-label, inpatient, five-
way crossover bioequivalence studies (Study 1, Study 2)
were conducted to evaluate the pharmacokinetics of
400-mg dose equivalents of IBU administered in various
different formulations. In both studies, subjects received all
interventions according to a computer-generated random
sequence provided by Pfizer Consumer Healthcare’s Bio-
statistics Department; treatment periods were separated by
a washout period of at least 48 h. Subjects remained on site
for the duration of each respective study.
In Study 1, conducted from July 29 to August 7, 2009, at
PPD Development, LP (Austin, TX, USA), subjects received
ibuprofen sodium dihydrate tablets [Advil Film-Coated
Tablets (IBUNa), Pfizer Consumer Healthcare, Madison, NJ,
USA] 2 9 256 mg, solubilized IBU liquid capsules [Advil
Liqui-Gels (IBULG), Pfizer Consumer Healthcare]
2 9 200 mg, and standard IBU tablets [Motrin IB (IBU-
Mot), McNeil Consumer Healthcare, Fort Washington, PA,
USA] 2 9 200 mg in each of three study periods following
an overnight fast. For the remaining two study periods,
subjects received IBUNa tablets 2 9 256 mg or IBULG
2 9 200 mg within 20 min of a standardized high-fat
breakfast. In Study 2, conducted from June 9 to 18, 2010, at
Bio-Kinetic Clinical Applications, LLC (Springfield, MO,
USA), subjects received IBUNa tablets 2 9 256 mg, solu-
bilized IBU liquid capsules [Advil FastGel (IBUFG),
Pfizer Consumer Healthcare] 2 9 200 mg, two formulations
of standard IBU tablets [Nurofen (IBUNur), Reckitt
Benckiser, Slough, Berkshire, UK; and Advil (IBUAdv),
Pfizer Consumer Healthcare] 2 9 200 mg, and caplets of
NurofenExpress containing IBU lysinate (IBULys) (Reckitt
Benckiser) 2 9 342 mg following an overnight fast.
Both protocols were approved by the appropriate insti-
tutional review board prior to study initiation, and both
trials were conducted in compliance with International
Conference on Harmonisation (ICH) standards for Good
Clinical Practice and the Declaration of Helsinki and its
amendments. All subjects provided written informed con-
sent prior to the conduct of any study-related procedures.
2.2 Subjects
Subjects for Studies 1 and 2 were adult male and female
(non-pregnant and non-lactating) volunteers in normal
physical health, as determined by physical examination and
laboratory evaluation, between 18 and 45 years of age and
with a body mass index (BMI) of 18–29 kg/m2. Females of
childbearing potential were required to be using reliable
contraception. Excluded were individuals with a presence
or history of any significant systemic medical disorder or
condition felt to increase subject risk. Other exclusion
criteria included hypersensitivity to aspirin, IBU, or other
nonsteroidal anti-inflammatory drugs; alcohol or substance
abuse within 2 years of enrollment; tobacco use within
6 weeks of enrollment; use of an investigational drug or
participation in an investigational trial within 30 days of
study initiation; and participation in another pharmacoki-
netic study or donation of blood/plasma within 4 weeks of
the first treatment period, within 6 weeks of first treatment
if [300 mL of blood was contributed, within 8 weeks of
first treatment if [400 mL of blood was contributed, or
within 10 weeks of first treatment if hemoglobin or
hematocrit was noted to be abnormal.
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Eligible subjects agreed not to take any medications
(except oral contraceptives), nutritional supplements
(except vitamin and mineral supplements), weight loss or
energy products, herbal teas, or herbal supplements for
14 days prior to and during each study period. They also
agreed not to ingest caffeine for 24 h or alcohol for 3 days
prior to and during the study.
It was estimated that 30 subjects were needed for each
study to provide at least 80 % power to establish bio-
equivalence, assuming that the bioavailability of IBUNa
was within 7.5–9.0 % of that for the reference, and the
within-subject variability for Log Cmax was 0.178–0.187 or
less based on previous studies; additional subjects were
enrolled assuming an *15 % dropout rate to ensure at
least 30 subjects completed each study.
2.3 Bioanalysis
For IBU pharmacokinetic analyses, blood samples (3 mL
each, collected into sodium heparin tubes) were drawn
prior to dosing (hour 0) and at 10, 15, 20, 25, 30, 35, 40,
45, 50, 60, 75, and 90 min and at 2, 3, 4, 6, 8, 10, 12, and
16 h postdose. Once obtained, blood samples were mixed
thoroughly, put on ice, and centrifuged within 30 min of
collection. Following centrifugation, plasma was removed
and stored at -20 C until analyzed. Plasma was ana-
lyzed for racemic IBU using a validated method of high-
performance liquid chromatography with tandem mass
spectrometry detection. This method allowed for a lower
limit of IBU quantitation of 0.2 lg/mL. Expressed as a
percent coefficient of variation, the intra-assay precision
was 0.542–3.36 %; the inter-assay precision was
1.11–2.79 %.
2.4 Pharmacokinetic Parameters and Analysis
Only those subjects providing evaluable data from at least
two study treatment periods were included in the pharma-
cokinetic analyses of each study. Data were considered
inevaluable if two consecutive plasma concentrations were
missing for that period, predose plasma IBU concentration
was [5 % of Cmax for that period, or if the subject expe-
rienced emesis at or before two times the median Tmax for
that period. Concentrations below the limit of quantitation
(0.2 lg/mL) were set to zero.
Untransformed pharmacokinetic parameters were
derived using WinNonlin version 5.1 (Pharsight, Inc.,
Mountain View, CA, USA). The following parameters
were calculated based on actual sampling times: area under
the plasma concentration versus time curve to last obser-
vable concentration (AUCL) and from time zero to infinity
(AUCI), Cmax, Tmax, half-life, elimination rate constant,
volume of distribution, and clearance.
Data for AUCL, AUCI, and Cmax (log transformed) were
analyzed via analysis of variance (ANOVA) with effects
for sequence, subject (sequence), period, and treatment
terms in the model. For Study 1, fasting-state paired
comparisons were conducted between IBUNa versus IBULG
and IBUNa versus IBUMot; fed-state comparisons were
made between IBUNa versus IBULG. For Study 2, IBUNa
was compared with IBUFG, IBUNur, IBUAdv, and IBULys all
in the fasting state. Additionally, IBUFG was also compared
with IBUAdv. Bioequivalence was considered established if
the two-sided 90 % confidence interval (CI) for the least
squares means ratio of study drug to reference formulation
was between 80 and 125 %. Post hoc analyses of Tmax were
performed using the Wilcoxon rank-sum test; Hodges-
Lehmann estimates were used to evaluate treatment dif-
ferences. No other changes were made to the planned
protocols following initiation of the studies. Statistical
analyses were performed using SAS version 9.2 (SAS
Institute, Cary, NC, USA).
2.5 Safety Analysis
Safety was evaluated among all subjects who took at least
one dose of study medication. Adverse events (AEs) were
coded using the Medical Dictionary for Regulatory Activ-
ities (Study 1, version 9.0; Study 2, version 13.0) and
classified by severity and relationship to study medication.
Prestudy and poststudy physical examinations and labora-
tory findings of clinical relevance were recorded.
3 Results
3.1 Subject Disposition and Baseline Demographics
Seventy-one healthy adults (N = 36 in Study 1 and N = 35
in Study 2) were randomized to receive study medication.
Seven subjects discontinued prematurely, including four
subjects in Study 1 (two voluntary withdrawals due to
painful blood collections and two due to AEs) and three
subjects in Study 2 (two due to AEs and one due to
uncooperativeness). In Study 1, all four subjects who dis-
continued early (during treatment period 1) were excluded
from all pharmacokinetic analyses; three additional sub-
jects had data excluded for specific periods. In Study 2, one
subject discontinued early (treatment period 1) and was
excluded from all pharmacokinetic analyses; four addi-
tional subjects had data excluded from specific periods.
The demographic characteristics (Table 1) of subjects
enrolled in Studies 1 and 2 were generally similar in terms
of age, weight, height, and BMI; approximately equal
proportions of male and female subjects participated. Most
subjects in both studies were white.
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3.2 IBU Pharmacokinetic Results
Mean IBU plasma concentration versus time curves and
pharmacokinetic results for Study 1 are presented in Fig. 1
and Table 2, respectively. Using log-transformed data,
IBUNa demonstrated an equivalent extent of absorption
relative to IBUMot in the fasted state on the basis of AUCL;
the 90 % CI for AUCI was also contained within the limits
of bioequivalence. However, IBUNa reached a Cmax that
was higher (90 % CI 125.2–145.5) than that for IBUMot.
Additionally, the Tmax for IBUNa was 82.0 min faster
(95 % CI 62.1–108.0, P \ 0.001) (Table 3) than that for
IBUMot.
Comparisons of IBUNa and IBULG indicated bioequiv-
alence under both fasted and fed conditions for both the
rate and extent of IBU absorption. The 90 % CIs for the
AUCI were in line with AUCL findings. As expected, the
rate of IBU absorption with IBUNa and IBULG was slower
in the fed state than in the fasted state (Fig. 1 and Table 2).
Mean IBU plasma concentration versus time curves and
pharmacokinetic results for Study 2 are presented in Fig. 2
and Table 4. Compared with standard IBU formulations
(IBUAdv and IBUNur), IBUNa had an equivalent extent of
absorption (AUCL); the 90 % CIs for AUCI were also
within the limits of bioequivalence. IBUNa was absorbed
significantly faster compared with IBUAdv and IBUNur;
Cmax was higher (90 % CI 117.5–136.4) for IBUNa versus
IBUAdv and was also greater (90 % CI 121.3–140.5) for
IBUNa versus IBUNur. As summarized in Table 3, the Tmax
for IBUNa was faster than that for IBUAdv and IBUNur,
(P \ 0.001 for both comparisons).
IBUNa was bioequivalent to both IBUFG and IBULys on
the basis of Cmax and AUCL. There were no significant
differences in Tmax between IBUNa and either IBUFG or
IBULys.
3.3 Safety and Tolerability
Four subjects prematurely discontinued from these studies
due to an AE (Study 1: one each for emesis and headache;
Study 2: one each for hemorrhoids and contact dermatitis).
Fifteen subjects from Study 1 reported 31 AEs; 14/31
(45.2 %) were considered treatment related, and all were
rated as mild except for one report each of nausea,
Table 1 Baseline demographics
Study 1 (N = 36) Study 2 (N = 35)
Age, mean (range), years 27.4 (18–45) 25.6 (18–45)
Weight, mean (range), kg 68.4 (50.8–94.3) 71.9 (50.6–95.8)
Height, mean (range), cm 169.1 (155–190) 173.1
(157.0–197.0)
BMI, mean (range), kg/m2 23.9 (19–28) 23.9 (18.8–28.9)
Race, N (%)
White 31 (86.1) 33 (94.3)
Black 4 (11.1) 0
Asian 1 (2.8) 1 (2.9)
Other 0 1 (2.9)
Ethnicity, N (%)
Non-Hispanic 19 (52.8) 32 (91.4)
Hispanic 17 (47.2) 3 (8.6)
Sex, N (%)
Male 18 (50) 18 (51.4)
Female 18 (50) 17 (48.6)
BMI body mass index (height in meters/mass in kg2), N number
Fig. 1 Study 1: Mean
ibuprofen (IBU) plasma
concentrations from time 0
(predose) to hour 16 postdose in
subjects administered 400-mg
dose equivalents of IBU via a
novel IBU sodium dihydrate
tablet (Advil Film-Coated
Tablets; IBUNa) and Advil

Liqui-Gels liquid capsules
(IBULG) under fed and fasted
conditions and Motrin IB
tablets (IBUMot) under fasted
conditions
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vomiting, headache, and blurred vision of moderate
severity. The most common AE among all treatments in
Study 1 was headache (six reports). In Study 2, 17 subjects
reported 35 AEs; 9/35 (25.7 %) were considered treatment
related, and all were rated as mild. The most common AE
across all treatments in Study 2 was dizziness (12 reports).
No severe or serious AEs occurred during either study.
With the exception of the development of a mild ear
infection that resolved spontaneously without any treat-
ment in one subject in Study 2, there were no clinically
significant laboratory, vital sign, or physical examination
findings noted during either study. No new or unexpected
safety concerns emerged in the IBUNa arms versus those of
comparator IBU formulations; AE rates were similar across
all treatments (data not shown).
4 Discussion
Results of the two pharmacokinetic studies presented here
demonstrate that this novel formulation of IBUNa was
absorbed at a rate faster than standard IBU tablets and was
comparable with rates of other fast-absorbed IBU formu-
lations. IBUNa was bioequivalent to IBULG, IBUFG, and
IBULys in terms of both the rate and extent of absorption in
the fasted state. Tmax was approximately 5–10 min faster
with IBUNa than IBULG in the fasted state. Feeding had a
similar effect on the rate of absorption of both IBUNa and
IBULG, as both Cmax and Tmax were similar between the
two formulations in both the fasted and fed states. IBUNa
was absorbed to the same extent as standard IBU when
administered as IBUMot, IBUAdv, and IBUNur, but was
absorbed more rapidly, with Tmax values of 30–35 min
versus 120, 82.5, and 120 min, respectively. All IBU
treatments were well tolerated.
IBU formulations that employ IBU dissolved in a gelatin
capsule or conjugated to a salt allow healthy subjects to
more rapidly absorb the product and in this way improve
upon the relatively low solubility of standard tablets that
are composed of IBU free acid. Since IBU is almost
entirely absorbed, faster absorption does not increase the
extent of absorption; hence, overall IBU exposure is similar
to that of standard IBU, as shown in previous studies [2, 6].
Pharmacodynamic investigations have demonstrated that
faster absorption of IBU arginate is associated with a faster
onset of analgesia compared with standard IBU tablets [4,
5]. Furthermore, in a study modeling the pharmacokinetics
and pharmacodynamics of an effervescent formulation of
IBU, faster absorption of that formulation was also asso-
ciated with faster onset of analgesia in patients with dental
pain compared with standard IBU [12].
Similarly, IBUNa tablets have been designed with this
same goal in mind. IBU is a carboxylic acid that does not
rapidly dissolve in an acidic aqueous environment such as
that of the stomach [3]. In vitro investigations have shown
a significantly faster rate of dissolution for IBUNa com-
pared with standard IBU tablets at acidic pH levels [13].
The current findings demonstrate that these novel IBUNa
Table 2 Study 1 pharmacokinetic parameters and bioequivalence
Treatment (N) AUCL (lgh/mL) AUCI (lgh/mL) Cmax (lg/mL) t (h) Kel (1/h) CL (L/h) Vd (L)
Mean (SD)









































LSM ratios, % (90 % CI)a
IBUNa/IBULG fasted
b 102.0 (99.1–105.0) 102.0 (99.1–105.0) 104.2 (96.6–112.4) – – – –
IBUNa/IBUMot fasted
b 102.4 (99.5–105.4) 101.8 (98.9–104.8) 135.0 (125.2–145.5) – – – –
IBUNa/IBULG fed
b 101.7 (98.8–104.7) 102.1 (99.2–105.1) 91.2 (84.6–98.3) – – – –
a Based on fitted log-transformed data
b Reference formulation
AUCI area under the plasma concentration vs. time curve from time 0 to infinity, AUCL area under the plasma concentration vs. time curve from
time 0 to last measurable concentration, CI confidence interval, CL clearance, Cmax maximum measured plasma concentration, IBU ibuprofen,
IBULG Advil
 Liqui-Gels liquid capsules, IBUMot Motrin
 IB tablets, IBUNa Advil
 Film-Coated Tablets, Kel elimination rate constant, LSM
least squares mean, N number, SD standard deviation, t half-life, Vd volume of distribution
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tablets, which have a thin-film coating and are manufac-
tured using a patent-pending process, provide faster
absorption with a more rapid attainment of peak IBU
plasma concentrations compared with standard IBU tablets.
Under fasted conditions, Cmax for IBUNa was approxi-
mately 30 % greater and Tmax occurred roughly 1–1.5 h
sooner than for standard IBU tablets. Importantly, AUCL
values for IBUNa and each of the standard IBU tablets
tested were similar, indicating that conjugation of IBU with
sodium salt does not alter the extent of IBU absorption and
yields overall IBU exposure similar to conventional IBU
tablets.
Our results are consistent with those of previous phar-
macokinetic evaluations of older formulations of IBUNa. In a
pair of open-label, randomized, single-dose, crossover
studies conducted in healthy volunteers, Sorgel et al. [13]
compared the pharmacokinetics of IBUNa with those of
standard IBU tablets, IBULys, and IBULG (first study), as
well as with IBUArg and IBULys (second study). These
studies have shown that IBUNa had a significantly higher
Cmax (47.6 vs. 36.8 lg/mL, P \ 0.01) and shorter Tmax (0.6
vs. 1.4 h, P = 0.018) compared with standard IBU tablets
and had no significant differences in absorption rate com-
pared with IBULys, IBUArg, or IBULG [13]. Similarly,
Dewland et al. [14] compared the single-dose pharmacoki-
netics (400-mg equivalents) of IBUNa with those of a novel
IBU/poloxamer formulation and standard IBU tablets in
healthy volunteers. While the overall extent of absorption
was similar for all of the formulations, Tmax averaged 55 min
shorter with IBUNa compared with standard IBU tablets
(median of 35 vs. 90 min, respectively; P \ 0.0002), and
Cmax was approximately 30 % higher (41.47 vs. 31.88 lg/
mL, respectively). It is worth noting that the Tmax values for
IBUNa across both the current and previous pharmacokinetic
studies are comparable—between 30 and 36 min.
Patients suffering from acute pain desire pain relief as
quickly as possible. Previous studies have shown that the
rate and extent of IBU absorption may be impaired during
pain episodes when IBU is taken in its standard oral for-
mulation, but that fast-dissolving IBU formulations fare
much better in this regard [15, 16]. The current investiga-
tion did not characterize the pharmacokinetic/pharmaco-
dynamic profile of analgesia following IBUNa
administration. However, a clinical efficacy study using
this same IBUNa formulation found it to provide a faster
onset of analgesia compared with standard IBU in subjects
with dental pain [17]. In that 8-h inpatient study examining
the effect of the current IBUNa formulation on postsurgical
dental pain using the third molar dental extraction model,
IBUNa was associated with a significantly earlier time to
meaningful pain relief (median 42.4 min) in comparison
with placebo ([8 h, P \ 0.001), pooled IBUAdv/IBUMot
(median 55.3 min, P \ 0.001), and IBUMot (median
60.7 min, P \ 0.001) and was marginally faster than
IBUAdv (median 52.0 min, P = 0.075) [17].
Two other randomized studies using previous IBUNa
formulations in the third molar extraction model of dental
pain showed similar findings [18, 19]. In the QUIKK trial,
first perceptible pain relief occurred 6 min earlier
(P = 0.004) with a previous IBUNa formulation than with
Table 3 Study 1 and Study 2 post hoc analysis of median Tmax
differences
Study 1
Treatment (N) Median Tmax (min)
IBUNa fasted (N = 32) 30.4
IBUNa fed (N = 32) 90.0
IBULG fasted (N = 30) 40.5
IBULG fed (N = 31) 90.0
IBUMot fasted (N = 31) 120.0
Study 1
Comparison Median difference (95 % CI)
in minutes and P valuesa
IBUNa vs. IBULG fasted 12.4 (7.1–18.3), P = 0.003
b
IBUNa vs. IBUMot fasted 82.0 (62.1–108.0), P \ 0.001
b
IBUNa vs. IBULG fed 0.0 (-30.0 to 14.5), P = 0.809
Study 2
Treatment (N) Median Tmax (min)
IBUNa (N = 33)
c 35.2
IBUFG (N = 31)
c 40.0
IBUNur (N = 33)
c 120.0
IBUAdv (N = 32)
c 82.5
IBULys (N = 32)
c 35.1
Study 2
Comparison Median difference (95 % CI)
in minutes and P valuesa
IBUNa vs. IBUFG 1.5 (-6.2 to 13.1), P = 0.527
IBUNa vs. IBUNur 75.2 (50.6–99.8), P \ 0.001
b
IBUNa vs. IBUAdv 63.8 (39.8–92.5), P \ 0.001
b
IBUNa vs. IBULys -2.3 (-9.8 to 5.1), P = 0.649
a Hodges–Lehmann estimator (median of the pairwise differences),
the 95 % CI and P values are from the Wilcoxon rank-sum test
b Statistically significant at the 0.05 level
c A total dose of two tablets/capsules/caplets was administered to
each subject with a total dose equivalent to 400 mg of IBU
CI confidence interval, IBU ibuprofen, IBUAdv Advil
 tablets, IBUFG
Advil FastGel liquid capsules, IBULG Advil
 Liqui-Gels liquid
capsules, IBULys Nurofen Express
 caplets containing IBU lysinate,
IBUMot Motrin
 IB tablets, IBUNa Advil
 Film-Coated Tablets,
IBUNur Nurofen
 tablets, N number, Tmax time to maximum measured
(i.e., peak) plasma concentration
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standard IBU tablets according to stopwatch assessments,
although the time to substantial pain relief was not sig-
nificantly different between the formulations [18]. Patient
diary assessments indicated that significantly more patients
treated with IBUNa reported ‘‘some’’ to ‘‘complete’’ pain
relief at 15 min (43 vs. 29 % for standard IBU tablets,
P \ 0.001) and at 30 min (82 vs. 63 %, P \ 0.001) [18].
In a study by Schleier et al. [19], the first sign of per-
ceptible pain relief occurred within 15 min for 52.5 % of
patients treated with a previous IBUNa formulation vs.
35.9 % of those treated with standard IBU tablets
(P \ 0.001). Substantial pain relief was attained after a
median of 42 versus 56 min with IBUNa versus standard
IBU [19]. In addition, reduction in pain intensity occurred
to a greater degree and was faster with IBUNa, such that
pain intensity was reduced by 50 % after an average of
30 min with IBUNa versus 57 min with standard IBU tab-
lets (P \ 0.02) [19]. Taken together, these data indicate
that the faster absorption achieved with various formula-
tions of IBUNa translates into more rapid pain relief.
Fig. 2 Study 2: Mean
ibuprofen (IBU) plasma
concentrations from time 0
(predose) to hour 16 postdose in
subjects administered 400-mg
dose equivalents of IBU under
fasted conditions via a novel






Express caplets containing IBU
lysinate (IBULys), standard
Advil tablets (IBUAdv), and
Nurofen tablets (IBUNur)
Table 4 Study 2 pharmacokinetic parameters and bioequivalence
Treatment (N) AUCL (lgh/mL) AUCI (lgh/mL) Cmax (lg/mL) t (h) Kel (1/h) CL (L/h) Vd (L)
Mean (SD)
IBUNa (N = 33) 140.8 (34.3) 142.1 (35.0) 47.0 (10.7) 2.12 (0.27) 0.33 (0.04) 2.96 (0.63) 8.84 (1.30)
IBUFG (N = 31) 133.8 (33.2) 135.2 (33.8) 46.8 (12.0) 2.17 (0.34) 0.33 (0.05) 3.11 (0.64) 9.59 (2.21)
IBUNur (N = 33) 140.5 (33.2) 141.9 (33.9) 36.1 (7.3) 2.17 (0.27) 0.32 (0.04) 2.95 (0.60) 9.10 (1.52)
IBUAdv (N = 32) 140.3 (30.3) 141.8 (31.1) 37.7 (8.4) 2.16 (0.28) 0.33 (0.04) 2.93 (0.56) 9.03 (1.49)
IBULys (N = 32) 136.4 (29.9) 137.7 (30.7) 49.9 (12.6) 2.16 (0.35) 0.33 (0.05) 3.03 (0.58) 9.20 (1.26)
LSM ratios, % (90 % CI)a
IBUNa/IBUFG
b 105.2 (102.1–108.3) 105.1 (102.1–108.1) 101.3 (94.0–109.2) – – – –
IBUNa/IBUNur
b 101.0 (98.1–103.9) 100.9 (98.1–103.8) 130.6 (121.3–140.5) – – – –
IBUNa/IBUAdv
b 100.3 (97.4–103.2) 100.2 (97.4–103.1) 126.6 (117.5–136.4) – – – –
IBUNa/IBULys
b 102.2 (99.3–105.2) 102.2 (99.4–105.2) 95.4 (88.6–102.8) – – – –
IBUFG/IBUAdv
b 95.4 (92.6–98.2) 95.4 (92.7–98.1) 125.0 (115.9–134.8) – – – –
a Based on fitted log-transformed parameters
b Reference formulation
AUCI area under the plasma concentration vs. time curve from time 0 to infinity, AUCL area under the plasma concentration vs. time curve from
time 0 to last measurable concentration, CI confidence interval, CL clearance, Cmax maximum measured plasma concentration, IBU ibuprofen,
IBUAdv Advil
 tablets, IBUFG Advil
 FastGel liquid capsules, IBULys Nurofen Express
 caplets containing IBU lysinate, IBUNa Advil
 Film-
Coated Tablets, IBUNur Nurofen
 tablets, Kel elimination rate constant, LSM least squares mean, N number, SD standard deviation, t half-life,
Vd volume of distribution
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The current studies are limited in that they were per-
formed in healthy volunteers, and therefore, the results
obtained may not be generalizable to those with underlying
comorbidities or to those with active pain. A previous study
found that pain was associated with an inhibition of
absorption of IBU and a decrease in the conversion of
racemic IBU to the active S-(?) enantiomer [15]. None-
theless, data from clinical studies utilizing the dental pain
model have shown a more rapid onset of analgesia with this
novel IBUNa formulation [17] as well as previous formu-
lations [18, 19] of IBUNa versus standard IBU formula-
tions, suggesting that although the absorption and
conversion of racemic IBU to the active S-(?) enantiomer
with this formulation may be delayed by pain, the faster-
absorbed formulation still provides faster onset of analge-
sia than standard formulations in the presence of pain.
Lastly, because subjects were not allowed to take con-
comitant medications while participating in these studies,
the potential for drug–drug interactions could not be
assessed. However, these would be expected to be the same
as those known for standard IBU.
5 Conclusions
A newly developed, novel tablet formulation of IBUNa was
absorbed more rapidly but achieved similar exposure in
comparison with standard IBU tablets in healthy volun-
teers. In addition, IBUNa was absorbed at the same rate as
other rapidly absorbed IBU formulations.
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